How much funding has Cairn Therapeutics raised?

Cairn Therapeutics has disclosed $3M raised across 1 round.

Where is Cairn Therapeutics headquartered?

Cairn Therapeutics is headquartered in Tucson, US.

Cairn Therapeutics

Tucson, US · Founded 2020 · Delaware corporation

Cairn Therapeutics is a biopharmaceutical company developing oncology treatments intended to address drawbacks of standard chemotherapy such as side effects, low potency, and multidrug resistance. Its lead candidate, CT-262, is based on duocarmycin drug chemistry invented by Dale Boger at Scripps Research.

BiotechHealthtech

Founders & leadership

Roger RajewskiNamed on SEC filing

George VielhauerNamed on SEC filing

Diarmuid BoranNamed on SEC filing

Dale BogerNamed on SEC filing

W. Scott EvangelistaCEO

Sutton FallerCOO

David G. BrooksCMO

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2021

▶$3MraisedSep 2021 · 27 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Roger RajewskiDirector
George VielhauerExecutive Officer
Diarmuid BoranExecutive Officer, Director
Dale BogerDirector
W. Scott EvangelistaDirector

Offering amount: $7.3M
Amount sold: $3M
Proceeds to insiders: $300K
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Kenaitx5 shared keywordsKenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease. Its lead program, RNDP-001, is being evaluated in the REPLACE Phase 1b/2a clinical trial for idiopathic Parkinson's disease.

Linnaeus Therapeutics4 shared keywordsClinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.

Marengo Therapeutics4 shared keywordsMarengo Therapeutics develops immunotherapies focused on activating specific immune cells to treat cancer. The company works in the oncology and immuno-oncology biotech space.

City Therapeutics4 shared keywordsCity Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands. The company aims to expand RNAi therapeutics beyond liver targeting to additional cell and tissue types.

Companies competing with Cairn Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Cairn Therapeutics do?: Cairn Therapeutics is a biopharmaceutical company developing oncology treatments intended to address drawbacks of standard chemotherapy such as side effects, low potency, and multidrug resistance. Its lead candidate, CT-262, is based on duocarmycin drug chemistry invented by Dale Boger at Scripps Research.
How much funding has Cairn Therapeutics raised?: Cairn Therapeutics has disclosed $3M raised across 1 round.
Where is Cairn Therapeutics headquartered?: Cairn Therapeutics is headquartered in Tucson, US.